MedTrace Logo

The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

NCT04799743 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-07-16

No results posted yet for this study

Summary

A randomized controlled trial (RCT) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients.

Conditions

Interventions

DRUG

Resveratrol

Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.

DRUG

Placebo capsules

The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.

Sponsors & Collaborators

  • Hospital Authority, Hong Kong

    collaborator OTHER_GOV

  • Hong Kong Baptist University

    lead OTHER

Principal Investigators

  • Bian Zhaoxiang, MD.,PH.D · Hong Kong Chinese Medicine Clinical Study Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04799743 on ClinicalTrials.gov